...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Two More Promissory Notes

Promissory Note: Dated 2024-09-11 for $ 135,890.00

With 135K warrants @ $1.02 expire, 2029-09-11

Out of Alberta (Accredited Investor)

 

Promissory Note: Dated 2024-10-09 for $ 629,740.00

With 625K warrants @ $1.03 expire, 2029-10-09

Out of Alberta (Accredited Investor)

 

Koo

 

 

 

Share
New Message
Please login to post a reply